Renal transplantation in a patient with Bartter syndrome and glomerulosclerosis by Se Eun Lee et al.
DOI: 10.3345/kjp.2011.54.1.36 
Korean J Pediatr 2011;54(1):36-39
Case report
36
Renal transplantation in a patient with Bartter syn-
drome and glomerulosclerosis
Bartter syndrome (BS) is a clinically and genetically heterogeneous 
inherited renal tubular disorder characterized by renal salt wasting, 
hypokalemic metabolic alkalosis and normotensive hyperreninemic 
hyperaldosteronism. There have been several case reports of BS 
complicated by focal segmental glomerulosclerosis (FSGS). Here, 
we have reported the case of a BS patient who developed FSGS 
and subsequent end-stage renal disease (ESRD) and provided a brief 
literature review. The patient presented with classic BS at 3 months of 
age and developed proteinuria at 7 years. Renal biopsy performed at 
11 years of age revealed a FSGS perihilar variant. Hemodialysis was 
initiated at 11 years of age, and kidney transplantation was performed 
at 16 years of age. The post-transplantation course has been uneventful 
for more than 3 years with complete disappearance of BS without 
the recurrence of FSGS. Genetic study revealed a homozygous 
p.Trp(TGG)610Stop(TGA) mutation in the CLCNKB gene. In summary, 
BS may be complicated by secondary FSGS due to the adaptive 
response to chronic salt-losing nephropathy, and FSGS may progress to 
ESRD in some patients. Renal transplantation in patients with BS and 
ESRD results in complete remission of BS.
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possible link between the two diseases, and indicate that stimulation 
of the renin–angiotensin system (RAS) and increased angiotensin II 
in response to chronic glomerular hyperfiltration due to salt-losing 
tubulopathy may lead to secondary FSGS
3, 4, 8).
In addition to FSGS, several other factors have been reported to 
influence the renal survival of patients with BS, including recurrent 
episodes of dehydration during early infancy, chronic hypokalemia, 
long-term use of non-steroidal anti-inflammatory drugs, 
Introduction
Bartter syndrome (BS) is a rare inherited renal tubular disorder 
characterized by renal salt wasting, hypokalemic metabolic alkalosis 
and normotensive hyperreninemic hyperaldosteronism
1, 2). Although 
BS is a typical tubular disorder, there have been several case reports of 
patients who developed focal segmental glomerulosclerosis (FSGS), 
a glomerular lesion, during the course of BS
3-7). Such cases support a Korean J Pediatr 2011;54(1):36-39 • DOI: 10.3345/kjp.2011.54.1.36    37
nephrocalcinosis, and mutations in the BSND gene
9-11). However, 
there have been only a few case reports of patients with BS who 
underwent renal transplantation
6, 12-15).
Here, we present a case of a patient with BS who developed FSGS 
and subsequently underwent renal transplantation due to aggravation 
of his renal function. We also review previously reported cases of 
both diseases and cases of individuals with BS who underwent renal 
transplantation. 
 Case report
The male patient was born at term with a birth weight of 2.8 kg. 
There were no perinatal problems including polyhydramnios, and 
the family history was unremarkable. At age 3 months, the patient 
visited a hospital due to recurrent febrile episodes and poor weight 
gain. The patient was diagnosed as BS, and potassium supplement 
and indomethacin medication were started. However, his compliance 
to the drug was very poor. Detailed clinical and laboratory data from 
that time are unavailable.
At age 7, proteinuria was incidentally detected upon routine 
follow-up urinalysis. A renal ultrasonography revealed diffusely 
increased parenchymal echogenicity without definite evidence of 
nephrocalcinosis or nephrolithiasis. At age 8, a renal biopsy was 
conducted at the hospital due to persistent proteinuria (24-hour urine 
protein excretion 3,840 mg/day, serum albumin 3.4 g/dL, and serum 
creatinine 1.2 mg/dL). A biopsy revealed a perihilar type of segmental 
sclerosis in two of seven glomeruli. His proteinuria did not respond to 
4 weeks of oral prednisolone (2 mg/kg/day) treatment. 
At age 10, the patient was referred to our hospital due to pro  gressive 
azotemia. During this time, he was taking oral potassium, ibuprofen 
and enalapril. The patient’s height was 123cm (<3rd percentile), 
weight was 36 kg (90-97th percentile), and blood pressure was 
117/69 mmHg at the time of admission. The laboratory examination 
revealed a serum creatinine level of 3.1 mg/dL, a sodium level of 138 
mmol/L, a potassium level of 3.7 mmol/L, a chloride level of 103 
mmol/L, a bicarbonate level of 30 mEq/L, a magnesium level of 2.0 
mEq/L, a plasma renin activity of 83 ng/mL/hr (normal range 1-2.5), 
an aldosterone level of 558 pg/mL (normal range 50-194), and a spot 
urine calcium (mg) to creatinine (mg) ratio of 0.02. Additionally, the 
patient’s bone age was 6 years 5 months upon admission. Genetic 
analysis revealed a homozygous p.Trp(TGG)610Stop(TGA) 
mutation in exon 16 on the CLCNKB gene. His renal function 
deteriorated progressively for one year thereafter, at which point 
hemodialysis was started. Subsequently, the patient underwent 
renal transplantation successfully from a deceased donor at age 16. 
The post-transplantation course has been uneventful for more than 
3 years, with complete disappearance of BS without recurrence of 
FSGS. 
Discussion
BS is a heterogeneous disorder both clinically and genetically. 
Clinically, BS can be classified into two variants, antenatal/neonatal 
BS and classic BS according to the onset age. Genetically, BS can 
be classified into at least 5 subtypes according to underlying mutant 
genes, all of which are expressed in the tubular epithelial cells of 
the thick ascending limb of the loop of Henle. BS type I is caused 
by loss-of-function mutations of SLC12A1 encoding the apical 
sodium-potassium-chloride cotransporter (NKCC2), while BS type 
II is caused by loss-of-function mutations of KCNJ1 encoding the 
Table 1. Summary of Case Reports of Bartter Syndrome (BS) Complicated by Focal Segmental Glomerulosclerosis (FSGS)
Variables Ref. 3) Ref. 4) Ref. 5) Ref. 6) Ref. 7) Present case
Gender male male female female male male
BS variant classic?* classic classic antenatal classic classic
BS subtype n.a. type I type IV?
† n.a. type III  type III
Proteinura nephrotic nonnephrotic nephrotic  nephrotic nephrotic nephrotic
Age at biopsy 11 years 20 years 14 years 5 years 15 years 8 years 
FSGS variant n.a perihilar n.a. n.a collapsing or cellular?
‡ perihilar
Nephrocalcinosis (–) (+) (–) (–) (–) (–)
Use of NSAIDs
§  (–) (–) (–) (+) (+) (+)
Renal function (age, years) normal +  no PU (11) CRF (29) GFR 88 (15) CRF (5),  Tpl (7) normal + mild PU (19) CRF (10),  Tpl (16)
*The patient was diagnosed with BS with severe mental and growth retardation at age 10. However, he had a history of premature birth (28 weeks of gestation 
with a birth weight of 1,300 g) and there was no clear information regarding his perinatal and neonatal periods available.
†Genetic study of SLC12A1, KCNJ1 and CLCNKB revealed no mutation, and she had bilateral sensorineural hearing loss.
‡Two of eleven glomeruli showed FSGS characterized by cellular lesions such as the collapse of the glomerular capillaries and adhesions of the glomerular tuft 
with swollen and vacuolated podocytes
§Use of non-steroidal anti-inflammatory drugs prior to the onset of proteinuria
Abbreviations: Ref., reference, n.a., not available; PU, proteinuria; CRF, chronic renal failure; GFR, glomerular filtration rate (mg/hour/1.73m
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apical inwardly-rectifying potassium channel (ROMK), BS type 
III is caused by loss-of-function mutations of CLCNKB encoding 
the basolateral chloride channel (ClC-Kb), BS type IV is caused by 
loss-of-function mutations of BSND encoding barttin, and BS type 
V is caused by gain-of-function mutations of CASR encoding the 
basolateral calcium sensing receptor (CaSR)
2). Our patient presented 
with classic BS and CLCNKB mutations.
BS is an inherited tubular disorder; however, our patient developed 
FSGS, an acquired glomerular lesion, later in the disease course. 
There have been five similar case reports of BS complicated by 
FSGS
3-7) (Table 1). In addition, there is an additional report of a 
patient with classic BS who developed end-stage renal disease due 
to glomerulopathy
12). However, this patient was excluded from 
the review because the renal pathology was described as ‘diffuse’ 
glomerulosclerosis. As shown in Table 1, patients with BS and FSGS 
show development of FSGS independently of gender, clinical variants 
of BS or genetic subtypes of BS. One patient had nephrocalcinosis, 
and three patients had a history of long-term non-steroidal anti-
inflammatory drug treatment prior to the onset of proteinuria. FSGS 
was detected during childhood to young adult age in all six cases. 
Three patients had progressed to chronic renal failure, but the rate of 
progression was variable. One other patient revealed mildly decreased 
renal function one year after diagnosis with FSGS
5). Normal renal 
function was maintained in the remaining two patients, and, 
interestingly, proteinuria resolved completely in one of these patients 
after one year treatment with potassium supplements, spironolactone, 
and indomethacin
3). The renal pathologic findings were described 
in detail in three cases, two of which had perihilar type FSGS. The 
perihilar variant is common in patients with secondary forms of 
FSGS mediated by glomerular hyperfiltration or other adaptation 
after loss of renal mass
8, 16). These findings suggest that FSGS 
complicated by BS may be a secondary lesion due to adaptive response 
to chronic hyperfiltration by chronic salt-loss and resultant chronic 
stimulation of the renin-angiotensin system. Several case reports of 
Gitelman syndrome complicated by FSGS support this explanation
17, 
18).
Case reports of patients with BS who underwent renal trans-
plantation are also rare, and the causes of ESRD include pro-
gression of FSGS or other causes including complication of long-
term non-steroidal anti-inflammatory drug treatment
6, 12-15). In 
one of the patients, pre-emptive bilateral native nephrectomies and 
renal transplantation were conducted prior to the onset of ESRD 
due to severe, clinically brittle, neonatal BS
15). In all of the cases, 
transplantation was successful and BS disappeared completely after 
transplantation as shown in our patient.
In summary, BS may be complicated by FSGS due to adaptive 
response to chronic salt-losing nephropathy, and FSGS may cause 
ESRD in some patients. Renal transplantation in patients with BS 
with ESRD results in complete remission of BS.
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